pharma · Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) · Advanced Solid Tumor
Daiichi Sankyo US
Daiichi Sankyo
Daiichi Sankyo US is a pharma organization headquartered in basking ridge, USA. Primary therapeutic focus areas include Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor, No medical conditio
Company details
- Status
- Public
- HQ
- 211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US
- Employees
- 4,386
- Programs
- 58
- Drugs
- 66
- Patents
- 0
Raludotatug Deruxtecan
Phase 2 · small molecule · Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)
Raludotatug Deruxtecan for Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC) is a Phase 2 program (small_molecule) at Daiichi Sankyo with 1 ClinicalTrials.gov record(s).
Internal code DS6000-126
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Daiichi Sankyo
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)
- Status
- active
- Trials
- 1